Rytelo: Dosage Form, Projected Sales, NCE-1 Date | Imetelstat

Rytelo

Rytelo is a prescription treatment for adults with low-to-intermediate-1 risk myelodysplastic syndromes (MDS) who have anemia and need frequent blood transfusions, and who haven’t responded to or can’t take erythropoiesis-stimulating agents (ESAs).

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Imetelstat
Innovator :

GERON CORP
Approval Date :

06-Jun-24
NCE-1 Date :

06-Jun-28
NCE Date :

06-Jun-29
Dosage Form :

Intravenous Powder
Strength :

EQ 47MG BASE/VIAL & EQ 188MG BASE/VIAL
Therapeutic Category :

Anticancer
Revenue ($M) :

77

Year-wise Projected Sales ($M) :

2025 :

269
2026 :

484
2027 :

734
2028 :

1,067
2029 :

1,371
2030 :

1,704
2031 :

2,028

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Rytelo

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?